Skip to product information
1 of 1

Tirzepatide (RUO) — 10mg

Tirzepatide (RUO) — 10mg

Regular price $199.99 USD
Regular price $209.99 USD Sale price $199.99 USD
Sale Sold out
Shipping calculated at checkout.

Tirzepatide is a novel dual GIP/GLP-1 receptor agonist — the first in its class to co-activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Featured in the landmark SURMOUNT-5 head-to-head trial against semaglutide and the SURPASS series. Used as a tool compound in preclinical research on incretin biology and dual receptor pharmacology.

Specification

  • Purity: 99%+ (HPLC verified)
  • Quantity: 10mg
  • Molecular Weight: 4813.5 g/mol
  • Form: Lyophilized powder
  • Third-party lab: Janoshik Analytical
  • Identity (MS): Confirmed on COA

⚠ For research use only. Not for human consumption. Not FDA-approved.

View full details
WHY RESEARCHERS CHOOSE US

Built Around Quality.
Backed By Transparency.

At Synthetix Labs, every batch is manufactured under strict quality standards and independently verified before release. From third-party laboratory testing to batch-specific Certificates of Analysis, our commitment is complete transparency and consistent research-grade quality.

Third-Party Tested
Batch-Specific COAs
99%+ Purity Standards
Fast USA Shipping
Research Grade Quality
Secure Checkout
Features
Synthetix Labs
Typical Suppliers
Third-Party Testing
Batch-Specific COA
Verified Purity
Research Grade Standards
Fast USA Fulfillment
Secure Checkout
Research Insights

Trusted By Researchers

Built on transparency, consistency, and independent verification. Here's what researchers value most about choosing Synthetix Labs.

87%

Trusted Product Quality

Researchers reported confidence in the consistency and quality of every batch received.

89%

Fast & Secure Delivery

Customers appreciated reliable fulfillment, secure packaging, and quick USA shipping.

93%

Would Purchase Again

Researchers indicated they would confidently order from Synthetix Labs again.

*Statistics based on internal customer feedback and recurring research orders.*